Psoriasis - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：487頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Psoriasis - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Psoriasis - Pipeline Review, H1 2014’, provides an overview of the Psoriasis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriasis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Psoriasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Psoriasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Psoriasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Psoriasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Psoriasis - Pipeline Review, H1 2014’, provides an overview of the Psoriasis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriasis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Psoriasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Psoriasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Psoriasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Psoriasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
Introduction 7
Psoriasis Overview 8
Therapeutics Development 9
Psoriasis - Therapeutics under Development by Companies 11
Psoriasis - Therapeutics under Investigation by Universities/Institutes 20
Psoriasis - Pipeline Products Glance 22
Psoriasis - Products under Development by Companies 26
Psoriasis - Products under Investigation by Universities/Institutes 36
Psoriasis - Companies Involved in Therapeutics Development 37
Psoriasis - Therapeutics Assessment 147
Drug Profiles 171
Psoriasis - Recent Pipeline Updates 392
Psoriasis - Dormant Projects 456
Psoriasis - Discontinued Products 459
Psoriasis - Product Development Milestones 460
Appendix 467
List of Tables
Number of Products under Development for Psoriasis, H1 2014 28
Number of Products under Development for Psoriasis - Comparative Analysis, H1 2014 29
Number of Products under Development by Companies, H1 2014 31
Number of Products under Development by Companies, H1 2014 (Contd..1) 32
Number of Products under Development by Companies, H1 2014 (Contd..2) 33
Number of Products under Development by Companies, H1 2014 (Contd..3) 34
Number of Products under Development by Companies, H1 2014 (Contd..4) 35
Number of Products under Development by Companies, H1 2014 (Contd..5) 36
Number of Products under Development by Companies, H1 2014 (Contd..6) 37
Number of Products under Development by Companies, H1 2014 (Contd..7) 38
Number of Products under Investigation by Universities/Institutes, H1 2014 40
Comparative Analysis by Late Stage Development, H1 2014 41
Comparative Analysis by Clinical Stage Development, H1 2014 42
Comparative Analysis by Early Stage Development, H1 2014 43
Comparative Analysis by Unknown Stage Development, H1 2014 44
Products under Development by Companies, H1 2014 45
Products under Development by Companies, H1 2014 (Contd..1) 46
Products under Development by Companies, H1 2014 (Contd..2) 47
Products under Development by Companies, H1 2014 (Contd..3) 48
Products under Development by Companies, H1 2014 (Contd..4) 49
Products under Development by Companies, H1 2014 (Contd..5) 50
Products under Development by Companies, H1 2014 (Contd..6) 51
Products under Development by Companies, H1 2014 (Contd..7) 52
Products under Development by Companies, H1 2014 (Contd..8) 53
Products under Development by Companies, H1 2014 (Contd..9) 54
Products under Investigation by Universities/Institutes, H1 2014 55
Psoriasis - Pipeline by Alcon, Inc., H1 2014 56
Psoriasis - Pipeline by Johnson & Johnson, H1 2014 57
Psoriasis - Pipeline by Amgen Inc., H1 2014 58
Psoriasis - Pipeline by Eli Lilly and Company, H1 2014 59
Psoriasis - Pipeline by GlaxoSmithKline plc, H1 2014 60
Psoriasis - Pipeline by Echo Therapeutics, Inc., H1 2014 61
Psoriasis - Pipeline by Stiefel Laboratories, Inc., H1 2014 62
Psoriasis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 63
Psoriasis - Pipeline by XenoPort, Inc., H1 2014 64
Psoriasis - Pipeline by ApoPharma Inc., H1 2014 65
Psoriasis - Pipeline by Piramal Enterprises Limited, H1 2014 66
Psoriasis - Pipeline by Celltrion, Inc., H1 2014 67
Psoriasis - Pipeline by Dr. Reddy's Laboratories Limited, H1 2014 68
Psoriasis - Pipeline by LEO Pharma A/S, H1 2014 69
Psoriasis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2014 70
Psoriasis - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2014 71
Psoriasis - Pipeline by Pfizer Inc., H1 2014 72
Psoriasis - Pipeline by UCB S.A., H1 2014 73
Psoriasis - Pipeline by Cell Therapeutics, Inc., H1 2014 74
Psoriasis - Pipeline by Sun Pharmaceutical Industries Limited, H1 2014 75
Psoriasis - Pipeline by Celgene Corporation, H1 2014 76
Psoriasis - Pipeline by OPKO Health, Inc., H1 2014 77
Psoriasis - Pipeline by 4SC AG, H1 2014 78
Psoriasis - Pipeline by Addex Therapeutics, H1 2014 79
Psoriasis - Pipeline by AlbireoPharma, H1 2014 80
Psoriasis - Pipeline by Can-Fite BioPharma Ltd., H1 2014 81
Psoriasis - Pipeline by Almirall, S.A., H1 2014 82
Psoriasis - Pipeline by Basilea Pharmaceutica AG, H1 2014 83
Psoriasis - Pipeline by Bionomics Limited, H1 2014 84
Psoriasis - Pipeline by NicOx S.A., H1 2014 85
Psoriasis - Pipeline by Nuvo Research Inc., H1 2014 86
Psoriasis - Pipeline by Compugen Ltd., H1 2014 87
Psoriasis - Pipeline by Arena Pharmaceuticals, Inc., H1 2014 88
Psoriasis - Pipeline by Cytos Biotechnology AG, H1 2014 89
Psoriasis - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2014 90
Psoriasis - Pipeline by Uni-Bio Science Group Ltd., H1 2014 91
Psoriasis - Pipeline by Synta Pharmaceuticals Corp., H1 2014 92
Psoriasis - Pipeline by Panacea Biotec Limited, H1 2014 93
Psoriasis - Pipeline by Sareum Holdings plc, H1 2014 94
Psoriasis - Pipeline by Hybrigenics S.A., H1 2014 95
Psoriasis - Pipeline by Paloma Pharmaceuticals, Inc., H1 2014 96
Psoriasis - Pipeline by Morphotek, Inc., H1 2014 97
Psoriasis - Pipeline by Advinus Therapeutics Ltd., H1 2014 98
Psoriasis - Pipeline by Affimed Therapeutics AG, H1 2014 99
Psoriasis - Pipeline by Jenrin Discovery, Inc., H1 2014 100
Psoriasis - Pipeline by Upsher-Smith Laboratories, Inc., H1 2014 101
Psoriasis - Pipeline by Philogen S.p.A., H1 2014 102
Psoriasis - Pipeline by Farmacija d.o.o. Tuzla, H1 2014 103
Psoriasis - Pipeline by Foamix Ltd., H1 2014 104
Psoriasis - Pipeline by Acceleron Pharma, Inc., H1 2014 105
Psoriasis - Pipeline by Pieris AG, H1 2014 106
Psoriasis - Pipeline by Phenex Pharmaceuticals AG, H1 2014 107
Psoriasis - Pipeline by Argos Therapeutics, Inc., H1 2014 108
Psoriasis - Pipeline by Anacor Pharmaceuticals, Inc., H1 2014 109
Psoriasis - Pipeline by AnaptysBio, Inc., H1 2014 110
Psoriasis - Pipeline by Allozyne, Inc., H1 2014 111
Psoriasis - Pipeline by Coronado Biosciences, Inc., H1 2014 112
Psoriasis - Pipeline by Gene Signal International SA., H1 2014 113
Psoriasis - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2014 114
Psoriasis - Pipeline by Syntrix Biosystems, Inc., H1 2014 115
Psoriasis - Pipeline by Grupo Ferrer Internacional, S.A., H1 2014 116
Psoriasis - Pipeline by Hydra Biosciences, Inc., H1 2014 117
Psoriasis - Pipeline by Effimune SAS, H1 2014 118
Psoriasis - Pipeline by Kainos Medicine, Inc., H1 2014 119
Psoriasis - Pipeline by Virobay Inc., H1 2014 120
Psoriasis - Pipeline by Sosei Co. Ltd., H1 2014 121
Psoriasis - Pipeline by Y's Therapeutics Co., Ltd., H1 2014 122
Psoriasis - Pipeline by Welichem Biotech Inc., H1 2014 123
Psoriasis - Pipeline by Redox Pharmaceutical Corporation, H1 2014 124
Psoriasis - Pipeline by Cellceutix Corporation, H1 2014 125
Psoriasis - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2014 126
Psoriasis - Pipeline by Vitae Pharmaceuticals, Inc., H1 2014 127
Psoriasis - Pipeline by Kinex Pharmaceuticals, LLC, H1 2014 128
Psoriasis - Pipeline by SWITCH Biotech LLC, H1 2014 129
Psoriasis - Pipeline by Hy BioPharma Inc., H1 2014 130
Psoriasis - Pipeline by KAHR medical Ltd., H1 2014 131
Psoriasis - Pipeline by Pharis Biotec GmbH, H1 2014 132
Psoriasis - Pipeline by Covagen AG, H1 2014 133
Psoriasis - Pipeline by Lycera Corp., H1 2014 134
Psoriasis - Pipeline by Crescendo Biologics Limited, H1 2014 135
Psoriasis - Pipeline by Fibrocell Science, Inc., H1 2014 136
Psoriasis - Pipeline by AngioLab, Inc., H1 2014 137
Psoriasis - Pipeline by Laila Pharmaceuticals Pvt. Ltd., H1 2014 138
Psoriasis - Pipeline by GlycoMar Limited, H1 2014 139
Psoriasis - Pipeline by Sigmoid Pharma Ltd., H1 2014 140
Psoriasis - Pipeline by Advancell, H1 2014 141
Psoriasis - Pipeline by Selvita S.A, H1 2014 142
Psoriasis - Pipeline by Complix NV, H1 2014 143
Psoriasis - Pipeline by Corridor Pharmaceuticals Inc., H1 2014 144
Psoriasis - Pipeline by PurGenesis Technologies Inc., H1 2014 145
Psoriasis - Pipeline by Brickell Biotech, Inc., H1 2014 146
Psoriasis - Pipeline by Apexigen, Inc., H1 2014 147
Psoriasis - Pipeline by Dermadis SA, H1 2014 148
Psoriasis - Pipeline by Ensemble Therapeutics Corporation, H1 2014 149
Psoriasis - Pipeline by Kadmon Pharmaceuticals, LLC, H1 2014 150
Psoriasis - Pipeline by Delenex Therapeutics AG, H1 2014 151
Psoriasis - Pipeline by Ajinomoto Pharmaceuticals Co., Ltd., H1 2014 152
Psoriasis - Pipeline by Avexxin AS., H1 2014 153
Psoriasis - Pipeline by Immune Response BioPharma, Inc., H1 2014 154
Psoriasis - Pipeline by Visionary Pharmaceuticals, Inc., H1 2014 155
Psoriasis - Pipeline by Oncobiologics, Inc., H1 2014 156
Psoriasis - Pipeline by Creabilis SA, H1 2014 157
Psoriasis - Pipeline by sterna biologicals Gmbh & Co KG, H1 2014 158
Psoriasis - Pipeline by Curaxys, S.L., H1 2014 159
Psoriasis - Pipeline by RAPID Pharmaceuticals AG, H1 2014 160
Psoriasis - Pipeline by ChironWells GmbH, H1 2014 161
Psoriasis - Pipeline by Pharmedartis GmbH, H1 2014 162
Psoriasis - Pipeline by vida therapeutics inc., H1 2014 163
Psoriasis - Pipeline by Aurinia Pharmaceuticals Inc., H1 2014 164
Psoriasis - Pipeline by Medac Pharma, Inc., H1 2014 165
Assessment by Monotherapy Products, H1 2014 166
Assessment by Combination Products, H1 2014 167
Number of Products by Stage and Target, H1 2014 170
Number of Products by Stage and Mechanism of Action, H1 2014 178
Number of Products by Stage and Route of Administration, H1 2014 186
Number of Products by Stage and Molecule Type, H1 2014 189
Psoriasis Therapeutics - Recent Pipeline Updates, H1 2014 411
Psoriasis - Dormant Projects, H1 2014 475
Psoriasis - Discontinued Products, H1 2014 478
List of Figures
Number of Products under Development for Psoriasis, H1 2014 28
Number of Products under Development for Psoriasis - Comparative Analysis, H1 2014 29
Number of Products under Development by Companies, H1 2014 30
Number of Products under Investigation by Universities/Institutes, H1 2014 39
Comparative Analysis by Late Stage Development, H1 2014 41
Comparative Analysis by Clinical Stage Development, H1 2014 42
Comparative Analysis by Early Stage Products, H1 2014 43
Assessment by Monotherapy Products, H1 2014 166
Number of Products by Top 10 Target, H1 2014 168
Number of Products by Stage and Top 10 Target, H1 2014 169
Number of Products by Top 10 Mechanism of Action, H1 2014 176
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 177
Number of Products by Top 10 Route of Administration, H1 2014 184
Number of Products by Stage and Top 10 Route of Administration, H1 2014 185
Number of Products by Top 10 Molecule Type, H1 2014 187
Number of Products by Stage and Top 10 Molecule Type, H1 2014 188
Table of Contents 2
Introduction 7
Psoriasis Overview 8
Therapeutics Development 9
Psoriasis - Therapeutics under Development by Companies 11
Psoriasis - Therapeutics under Investigation by Universities/Institutes 20
Psoriasis - Pipeline Products Glance 22
Psoriasis - Products under Development by Companies 26
Psoriasis - Products under Investigation by Universities/Institutes 36
Psoriasis - Companies Involved in Therapeutics Development 37
Psoriasis - Therapeutics Assessment 147
Drug Profiles 171
Psoriasis - Recent Pipeline Updates 392
Psoriasis - Dormant Projects 456
Psoriasis - Discontinued Products 459
Psoriasis - Product Development Milestones 460
Appendix 467
List of Tables
Number of Products under Development for Psoriasis, H1 2014 28
Number of Products under Development for Psoriasis - Comparative Analysis, H1 2014 29
Number of Products under Development by Companies, H1 2014 31
Number of Products under Development by Companies, H1 2014 (Contd..1) 32
Number of Products under Development by Companies, H1 2014 (Contd..2) 33
Number of Products under Development by Companies, H1 2014 (Contd..3) 34
Number of Products under Development by Companies, H1 2014 (Contd..4) 35
Number of Products under Development by Companies, H1 2014 (Contd..5) 36
Number of Products under Development by Companies, H1 2014 (Contd..6) 37
Number of Products under Development by Companies, H1 2014 (Contd..7) 38
Number of Products under Investigation by Universities/Institutes, H1 2014 40
Comparative Analysis by Late Stage Development, H1 2014 41
Comparative Analysis by Clinical Stage Development, H1 2014 42
Comparative Analysis by Early Stage Development, H1 2014 43
Comparative Analysis by Unknown Stage Development, H1 2014 44
Products under Development by Companies, H1 2014 45
Products under Development by Companies, H1 2014 (Contd..1) 46
Products under Development by Companies, H1 2014 (Contd..2) 47
Products under Development by Companies, H1 2014 (Contd..3) 48
Products under Development by Companies, H1 2014 (Contd..4) 49
Products under Development by Companies, H1 2014 (Contd..5) 50
Products under Development by Companies, H1 2014 (Contd..6) 51
Products under Development by Companies, H1 2014 (Contd..7) 52
Products under Development by Companies, H1 2014 (Contd..8) 53
Products under Development by Companies, H1 2014 (Contd..9) 54
Products under Investigation by Universities/Institutes, H1 2014 55
Psoriasis - Pipeline by Alcon, Inc., H1 2014 56
Psoriasis - Pipeline by Johnson & Johnson, H1 2014 57
Psoriasis - Pipeline by Amgen Inc., H1 2014 58
Psoriasis - Pipeline by Eli Lilly and Company, H1 2014 59
Psoriasis - Pipeline by GlaxoSmithKline plc, H1 2014 60
Psoriasis - Pipeline by Echo Therapeutics, Inc., H1 2014 61
Psoriasis - Pipeline by Stiefel Laboratories, Inc., H1 2014 62
Psoriasis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 63
Psoriasis - Pipeline by XenoPort, Inc., H1 2014 64
Psoriasis - Pipeline by ApoPharma Inc., H1 2014 65
Psoriasis - Pipeline by Piramal Enterprises Limited, H1 2014 66
Psoriasis - Pipeline by Celltrion, Inc., H1 2014 67
Psoriasis - Pipeline by Dr. Reddy's Laboratories Limited, H1 2014 68
Psoriasis - Pipeline by LEO Pharma A/S, H1 2014 69
Psoriasis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2014 70
Psoriasis - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2014 71
Psoriasis - Pipeline by Pfizer Inc., H1 2014 72
Psoriasis - Pipeline by UCB S.A., H1 2014 73
Psoriasis - Pipeline by Cell Therapeutics, Inc., H1 2014 74
Psoriasis - Pipeline by Sun Pharmaceutical Industries Limited, H1 2014 75
Psoriasis - Pipeline by Celgene Corporation, H1 2014 76
Psoriasis - Pipeline by OPKO Health, Inc., H1 2014 77
Psoriasis - Pipeline by 4SC AG, H1 2014 78
Psoriasis - Pipeline by Addex Therapeutics, H1 2014 79
Psoriasis - Pipeline by AlbireoPharma, H1 2014 80
Psoriasis - Pipeline by Can-Fite BioPharma Ltd., H1 2014 81
Psoriasis - Pipeline by Almirall, S.A., H1 2014 82
Psoriasis - Pipeline by Basilea Pharmaceutica AG, H1 2014 83
Psoriasis - Pipeline by Bionomics Limited, H1 2014 84
Psoriasis - Pipeline by NicOx S.A., H1 2014 85
Psoriasis - Pipeline by Nuvo Research Inc., H1 2014 86
Psoriasis - Pipeline by Compugen Ltd., H1 2014 87
Psoriasis - Pipeline by Arena Pharmaceuticals, Inc., H1 2014 88
Psoriasis - Pipeline by Cytos Biotechnology AG, H1 2014 89
Psoriasis - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2014 90
Psoriasis - Pipeline by Uni-Bio Science Group Ltd., H1 2014 91
Psoriasis - Pipeline by Synta Pharmaceuticals Corp., H1 2014 92
Psoriasis - Pipeline by Panacea Biotec Limited, H1 2014 93
Psoriasis - Pipeline by Sareum Holdings plc, H1 2014 94
Psoriasis - Pipeline by Hybrigenics S.A., H1 2014 95
Psoriasis - Pipeline by Paloma Pharmaceuticals, Inc., H1 2014 96
Psoriasis - Pipeline by Morphotek, Inc., H1 2014 97
Psoriasis - Pipeline by Advinus Therapeutics Ltd., H1 2014 98
Psoriasis - Pipeline by Affimed Therapeutics AG, H1 2014 99
Psoriasis - Pipeline by Jenrin Discovery, Inc., H1 2014 100
Psoriasis - Pipeline by Upsher-Smith Laboratories, Inc., H1 2014 101
Psoriasis - Pipeline by Philogen S.p.A., H1 2014 102
Psoriasis - Pipeline by Farmacija d.o.o. Tuzla, H1 2014 103
Psoriasis - Pipeline by Foamix Ltd., H1 2014 104
Psoriasis - Pipeline by Acceleron Pharma, Inc., H1 2014 105
Psoriasis - Pipeline by Pieris AG, H1 2014 106
Psoriasis - Pipeline by Phenex Pharmaceuticals AG, H1 2014 107
Psoriasis - Pipeline by Argos Therapeutics, Inc., H1 2014 108
Psoriasis - Pipeline by Anacor Pharmaceuticals, Inc., H1 2014 109
Psoriasis - Pipeline by AnaptysBio, Inc., H1 2014 110
Psoriasis - Pipeline by Allozyne, Inc., H1 2014 111
Psoriasis - Pipeline by Coronado Biosciences, Inc., H1 2014 112
Psoriasis - Pipeline by Gene Signal International SA., H1 2014 113
Psoriasis - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2014 114
Psoriasis - Pipeline by Syntrix Biosystems, Inc., H1 2014 115
Psoriasis - Pipeline by Grupo Ferrer Internacional, S.A., H1 2014 116
Psoriasis - Pipeline by Hydra Biosciences, Inc., H1 2014 117
Psoriasis - Pipeline by Effimune SAS, H1 2014 118
Psoriasis - Pipeline by Kainos Medicine, Inc., H1 2014 119
Psoriasis - Pipeline by Virobay Inc., H1 2014 120
Psoriasis - Pipeline by Sosei Co. Ltd., H1 2014 121
Psoriasis - Pipeline by Y's Therapeutics Co., Ltd., H1 2014 122
Psoriasis - Pipeline by Welichem Biotech Inc., H1 2014 123
Psoriasis - Pipeline by Redox Pharmaceutical Corporation, H1 2014 124
Psoriasis - Pipeline by Cellceutix Corporation, H1 2014 125
Psoriasis - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2014 126
Psoriasis - Pipeline by Vitae Pharmaceuticals, Inc., H1 2014 127
Psoriasis - Pipeline by Kinex Pharmaceuticals, LLC, H1 2014 128
Psoriasis - Pipeline by SWITCH Biotech LLC, H1 2014 129
Psoriasis - Pipeline by Hy BioPharma Inc., H1 2014 130
Psoriasis - Pipeline by KAHR medical Ltd., H1 2014 131
Psoriasis - Pipeline by Pharis Biotec GmbH, H1 2014 132
Psoriasis - Pipeline by Covagen AG, H1 2014 133
Psoriasis - Pipeline by Lycera Corp., H1 2014 134
Psoriasis - Pipeline by Crescendo Biologics Limited, H1 2014 135
Psoriasis - Pipeline by Fibrocell Science, Inc., H1 2014 136
Psoriasis - Pipeline by AngioLab, Inc., H1 2014 137
Psoriasis - Pipeline by Laila Pharmaceuticals Pvt. Ltd., H1 2014 138
Psoriasis - Pipeline by GlycoMar Limited, H1 2014 139
Psoriasis - Pipeline by Sigmoid Pharma Ltd., H1 2014 140
Psoriasis - Pipeline by Advancell, H1 2014 141
Psoriasis - Pipeline by Selvita S.A, H1 2014 142
Psoriasis - Pipeline by Complix NV, H1 2014 143
Psoriasis - Pipeline by Corridor Pharmaceuticals Inc., H1 2014 144
Psoriasis - Pipeline by PurGenesis Technologies Inc., H1 2014 145
Psoriasis - Pipeline by Brickell Biotech, Inc., H1 2014 146
Psoriasis - Pipeline by Apexigen, Inc., H1 2014 147
Psoriasis - Pipeline by Dermadis SA, H1 2014 148
Psoriasis - Pipeline by Ensemble Therapeutics Corporation, H1 2014 149
Psoriasis - Pipeline by Kadmon Pharmaceuticals, LLC, H1 2014 150
Psoriasis - Pipeline by Delenex Therapeutics AG, H1 2014 151
Psoriasis - Pipeline by Ajinomoto Pharmaceuticals Co., Ltd., H1 2014 152
Psoriasis - Pipeline by Avexxin AS., H1 2014 153
Psoriasis - Pipeline by Immune Response BioPharma, Inc., H1 2014 154
Psoriasis - Pipeline by Visionary Pharmaceuticals, Inc., H1 2014 155
Psoriasis - Pipeline by Oncobiologics, Inc., H1 2014 156
Psoriasis - Pipeline by Creabilis SA, H1 2014 157
Psoriasis - Pipeline by sterna biologicals Gmbh & Co KG, H1 2014 158
Psoriasis - Pipeline by Curaxys, S.L., H1 2014 159
Psoriasis - Pipeline by RAPID Pharmaceuticals AG, H1 2014 160
Psoriasis - Pipeline by ChironWells GmbH, H1 2014 161
Psoriasis - Pipeline by Pharmedartis GmbH, H1 2014 162
Psoriasis - Pipeline by vida therapeutics inc., H1 2014 163
Psoriasis - Pipeline by Aurinia Pharmaceuticals Inc., H1 2014 164
Psoriasis - Pipeline by Medac Pharma, Inc., H1 2014 165
Assessment by Monotherapy Products, H1 2014 166
Assessment by Combination Products, H1 2014 167
Number of Products by Stage and Target, H1 2014 170
Number of Products by Stage and Mechanism of Action, H1 2014 178
Number of Products by Stage and Route of Administration, H1 2014 186
Number of Products by Stage and Molecule Type, H1 2014 189
Psoriasis Therapeutics - Recent Pipeline Updates, H1 2014 411
Psoriasis - Dormant Projects, H1 2014 475
Psoriasis - Discontinued Products, H1 2014 478
List of Figures
Number of Products under Development for Psoriasis, H1 2014 28
Number of Products under Development for Psoriasis - Comparative Analysis, H1 2014 29
Number of Products under Development by Companies, H1 2014 30
Number of Products under Investigation by Universities/Institutes, H1 2014 39
Comparative Analysis by Late Stage Development, H1 2014 41
Comparative Analysis by Clinical Stage Development, H1 2014 42
Comparative Analysis by Early Stage Products, H1 2014 43
Assessment by Monotherapy Products, H1 2014 166
Number of Products by Top 10 Target, H1 2014 168
Number of Products by Stage and Top 10 Target, H1 2014 169
Number of Products by Top 10 Mechanism of Action, H1 2014 176
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 177
Number of Products by Top 10 Route of Administration, H1 2014 184
Number of Products by Stage and Top 10 Route of Administration, H1 2014 185
Number of Products by Top 10 Molecule Type, H1 2014 187
Number of Products by Stage and Top 10 Molecule Type, H1 2014 188
